{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T05:53:36.417990+00:00","company":{"ticker":"PULM","cik":1574235,"company_name":"Pulmatrix, Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"b8fa9ede6b178c122537648f6be91a2ed9871ded","cik":1574235,"ticker":"PULM","company_name":"Pulmatrix, Inc.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"Cullgen Inc.","effective_date":"2026-02-28","item_codes_triggered":["1.02"],"value_text":null},"claim":"Pulmatrix, Inc. terminated Agreement and Plan of Merger and Reorganization with Cullgen Inc. (effective 2026-02-28).","evidence_excerpt":"Pulmatrix, Inc. (the “ Company ” or “ Pulmatrix ”) received a termination notice (the “ Notice ”) from Cullgen Inc. (“ Cullgen ”) pursuant to which Cullgen informed the Company that in accordance with Sections 11.7 and 10.1(b) of that certain Agreement and Plan of Merger and Reorganization, dated as of November 13, 2024, as amended by Amendment No. 1 thereto dated as of April 7, 2025 (the “ Merger Agreement ”), by and among the Company, Pulmatrix and PCL Merger Sub, Inc. and PCL Merger Sub Inc. II, LLC, Cullgen was terminating the Merger Agreement and all related transactions thereunder.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-008449","anchor_url":"https://secwatch.observer/filing/0001493152-26-008449#claim-b8fa9ede6b178c122537648f6be91a2ed9871ded","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315226008449/0001493152-26-008449-index.htm"},{"fact_type":"executive_change","fact_key":"2445d1e864","cik":1574235,"ticker":"PULM","company_name":"Pulmatrix, Inc.","filed_at":"2024-07-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-20","interim":true,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Peter Ludlum was appointed as Interim Chief Executive Officer at Pulmatrix, Inc..","evidence_excerpt":"the Board approved the appointment of Peter Ludlum as the Interim Chief Executive Officer (the “Interim CEO”), effective as of July 20, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-028507","anchor_url":"https://secwatch.observer/filing/0001493152-24-028507#claim-2445d1e864","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224028507/0001493152-24-028507-index.htm"},{"fact_type":"executive_change","fact_key":"be41846753","cik":1574235,"ticker":"PULM","company_name":"Pulmatrix, Inc.","filed_at":"2024-07-19T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-19","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Peter Ludlum","successor_named":true},"claim":"Teofilo Raad departed as Chief Executive Officer at Pulmatrix, Inc..","evidence_excerpt":"Effective as of the Separation Date, Mr. Raad’s employment with the Company shall cease and Mr. Raad shall relinquish all positions, offices, and authority with the Company and any affiliates, including as a member of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-028507","anchor_url":"https://secwatch.observer/filing/0001493152-24-028507#claim-be41846753","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224028507/0001493152-24-028507-index.htm"},{"fact_type":"earnings_release","fact_key":"6103f9307ca78a95fc81e0993788f756e166c75b","cik":1574235,"ticker":"PULM","company_name":"Pulmatrix, Inc.","filed_at":"2024-05-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.8 million","period_text":"three months ended March 31, 2024","report_date":"2024-05-10","result_type":"reported_results","revenue_text":"$5.9 million"},"claim":"Pulmatrix, Inc. reported three months ended March 31, 2024 results: revenue $5.9 million, net income $0.8 million.","evidence_excerpt":"outside\n the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900. First\nQuarter 2024 Financial Results Revenues\nincreased $4.4 million to $5.9 million for the three months ended March 31, 2024, compared to $1.5 million for the three months ended\nMarch 31, 2023. The increase is primarily related to a contract modification of the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018576","anchor_url":"https://secwatch.observer/filing/0001493152-24-018576#claim-6103f9307ca78a95fc81e0993788f756e166c75b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/0001493152-24-018576-index.htm"}]}